Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 24, Issue 5, Pages 1385-1392
Publisher
Oxford University Press (OUP)
Online
2012-12-18
DOI
10.1093/annonc/mds621
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CNS prophylaxis in diffuse large B-cell lymphoma: If, when, how and for whom?
- (2012) Tali Siegal et al. BLOOD REVIEWS
- High Ki67 Index and Bulky Disease Remain Significant Adverse Prognostic Factors in Patients with Diffuse Large B Cell Lymphoma before and after the Introduction of Rituximab
- (2011) Francesco Gaudio et al. ACTA HAEMATOLOGICA
- Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab
- (2011) W. M. Tai et al. ANNALS OF HEMATOLOGY
- R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group
- (2011) A. O. Gang et al. ANNALS OF ONCOLOGY
- Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium
- (2011) G. Salles et al. BLOOD
- Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era
- (2011) Anita Kumar et al. CANCER
- Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer
- (2011) Gary H. Lyman et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL
- (2010) G. Ott et al. BLOOD
- Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma
- (2010) Jeremy S. Abramson et al. CANCER
- Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
- (2010) Paul N. Meyer et al. JOURNAL OF CLINICAL ONCOLOGY
- A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy
- (2009) W. W.L. Choi et al. CLINICAL CANCER RESEARCH
- High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
- (2009) Andrés JM Ferreri et al. LANCET
- Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin's Lymphoma: A 20-Year Follow-Up Analysis of SWOG 8516—The Southwest Oncology Group
- (2008) Steven H. Bernstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
- (2008) Michael Pfreundschuh et al. LANCET ONCOLOGY
- Stromal Gene Signatures in Large-B-Cell Lymphomas
- (2008) G. Lenz et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now